Calliditas Therapeutics AB (FRA:LC8)
€ 17.83 0.06 (0.34%) Market Cap: 963.42 Mil Enterprise Value: 981.96 Mil PE Ratio: 0 PB Ratio: 104.30 GF Score: 51/100

Q1 2022 Calliditas Therapeutics AB Earnings Call Transcript

May 18, 2022 / 12:30PM GMT
Release Date Price: €7.62 (+9.09%)
Operator

Hello, and welcome to the Calliditas Therapeutics Audiocast with Teleconference Q1 2022. (Operator Instructions) And afterwards, there will be a question-answer session. I will now hand the call over to Renee Aguiar-Lucander, CEO. Please begin your meeting.

Renee Aguiar;Lucander;publ;CEO
Calliditas Therapeutics AB

()-

Thank you very much, and welcome to this Q1 2022 report from Calliditas Therapeutics. If you turn to Page 2 of the presentation, I would like to draw your attention to the disclaimer page related to forward-looking statements and refer you to the company's reports and other filings, including those which contain risk factor and other relevant sections of our public filings.

On this call today, I am joined by Andrew Udell, President North America; and Fredrik Johansson, Chief Financial Officer.

So if you turn to Page 3. So as you are all aware, it's the last quarter, Calliditas Therapeutics Q4, I would say, achieved a historic milestone in our history. We had our first commercial

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot